Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02973789 · ClinicalTrials.gov registry record · Phase 3
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
A Phase 3 study, sponsored by NovoCure.
- Completed
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
NCT02973789 is a Phase 3 study that has completed, run by NovoCure. The registered enrollment target is 291 participants.
The verdict
NCT02973789, a Phase 3 study, has completed, sponsored by NovoCure.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
Study Summary
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Interventions
- DEVICE NovoTTF-200T
- DRUG Immune checkpoint inhibitors or docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2016-12 |
| Est. Completion | 2024-10-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02973789
The ClinicalTrials.gov registry entry for NCT02973789 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovoCure, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NovoTTF-200T is the first listed.
NCT02973789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02973789 about?
NCT02973789 is a clinical study titled "Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)". The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment. The device is an experi...
What is the current status of trial NCT02973789?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2016-12. Estimated completion is 2024-10-09.
What interventions are being tested in trial NCT02973789?
The interventions under investigation include: NovoTTF-200T (DEVICE), Immune checkpoint inhibitors or docetaxel (DRUG).
Who is sponsoring clinical trial NCT02973789?
This trial is sponsored by NovoCure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.